secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2026-03-03T23:59:59+00:00
Accession:  0001140361-26-007447
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA accepts brepocitinib NDA for dermatomyositis, grants Priority Review; PDUFA Q3 2026
--------------------------------------------------------------------------------

- FDA accepted NDA and granted Priority Review for brepocitinib in dermatomyositis; PDUFA target action date in Q3 2026.
- Launch expected at end of September 2026 if approved; supported by positive Phase 3 VALOR trial (N=241).
- VALOR was first positive 52-week placebo-controlled study in dermatomyositis; brepocitinib 30mg met primary endpoint and all nine key secondary endpoints.
- If approved, brepocitinib would be first targeted therapy for dermatomyositis; safety profile similar to approved JAK/TYK2 inhibitors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036126007447/0001140361-26-007447-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036126007447/ef20066998_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-007447

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer